Real-World Evidence (RWE) for Drug Development

Challenge: Regulatory agencies increasingly require real-world evidence to support drug safety and effectiveness post-approval.

DeMedic Solution: Pharmaceutical companies and regulatory bodies can access anonymized patient datasets to analyze treatment outcomes, side effects, and population-level impact in real-world settings.

Example: After launching a new cardiovascular drug, a pharma company uses DeMedic to monitor recovery trends across age groups—helping improve post-market safety surveillance.